BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
4.440
+0.020 (0.45%)
At close: Jul 31, 2025, 4:00 PM
4.400
-0.040 (-0.90%)
After-hours: Jul 31, 2025, 4:00 PM EDT
Accolade Stock Forecast
Stock Price Forecast
The 3 analysts that cover Accolade stock have a consensus rating of "Hold" and an average price target of $5.67, which forecasts a 27.70% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $7.00.
Price Target: $5.67 (+27.70%)
Analyst Consensus: Hold
* Price targets were last updated on Mar 24, 2025.
Analyst Ratings
The average analyst rating for Accolade stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +12.61% | Mar 24, 2025 |
| Morgan Stanley | Morgan Stanley | Sell Initiates $5 | Sell | Initiates | $5 | +12.61% | Mar 7, 2025 |
| William Blair | William Blair | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Feb 28, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $45 → $7 | Strong Buy → Hold | Downgrades | $45 → $7 | +57.66% | Dec 9, 2024 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $42 → $7 | Strong Buy → Hold | Downgrades | $42 → $7 | +57.66% | Dec 9, 2024 |
Financial Forecast
Revenue This Year
2.56M
Revenue Next Year
1.70M
from 2.56M
Decreased by -33.35%
EPS This Year
-1.97
from -6.63
EPS Next Year
-2.30
from -1.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 7.0M | 7.0M | 7.0M |
| Avg | 2.6M | 1.7M | 1.7M |
| Low | 1.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 174.5% | 311.3% |
| Avg | - | -33.3% | -0.1% |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.37 | -1.25 | -1.49 |
| Avg | -1.97 | -2.30 | -2.38 |
| Low | -2.86 | -2.98 | -2.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.